$32 Million Financing Round Fuels N-Power Medicine's Oncology Research Expansion

N-Power Medicine, an oncology drug development platform, has secured $32 million in Series B financing to expand its community oncology clinical research network and adopt its Prospective External Control Arms (ProECA) technology. The funding round features Labcorp Venture Fund as a new strategic investor, alongside continued participation from Merck Global Health Innovation Fund, Innovatus Capital Partners, and a leading U.S.-based biotechnology investor.

N-Power's ProECA platform solves a critical clinical trial bottleneck by generating trial-grade external control arms directly from routine community cancer care. This reduces the need for traditional patient randomization, decreases trial sample size requirements, and compresses drug development timelines.

The new capital will accelerate the expansion of N-Power's community research footprint and drive broader biopharma adoption of ProECA. The platform is currently used by biopharma sponsors to accelerate early-phase and Phase 4 post-market studies in non-small cell lung cancer (NSCLC), with plans to roll out platforms for colorectal cancer and prostate cancer later this year.